

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**  
**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2009

**THE QUIGLEY CORPORATION**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other  
jurisdiction of incorporation)

**0-21617**  
(Commission  
File Number)

**23-2577138**  
(I.R.S. Employer  
Identification No.)

**Kells Building,**  
**621 Shady Retreat Road, P.O. Box 1349**  
**Doylestown, PA**  
(Address of principal executive offices)

**18901**  
(Zip Code)

Registrant's telephone number, including area code: **(215) 345-0919**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions *see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(c) On July 15, 2009, Mr. Ted Karkus, the Chairman of the Board of The Quigley Corporation (the “**Company**”) and its Interim Chief Executive Officer, was appointed as Chief Executive Officer of the Company. Robert V. Cuddihy, Jr. was also appointed as Chief Operating Officer of the Company.

Mr. Karkus will earn a salary of \$750,000 per year as Chief Executive Officer and will receive regular benefits routinely provided to senior executives of the Company. There is no employment agreement memorializing the agreement between Mr. Karkus and the Company. Mr. Karkus does not have a family relationship with any director or executive officer of the Company, nor is he a party to any “related person” transactions with the Company.

Mr. Karkus, age 50, is Chairman of the Board of the Company. He is the managing member of Forrester Financial, LLC which he founded in 2001. Forrester is a management consulting firm providing a wide range of services to emerging-growth companies. Forrester’s services include the structuring and raising of working capital as well as assisting management in developing operational, marketing and financial strategies. He is the primary investor in all portfolio company financings. Mr. Karkus has extensive relationships with investment bankers, the media and a network of institutional investors and high net worth individuals. Mr. Karkus was instrumental in assisting the turn around of ID Biomedical, an influenza vaccine manufacturer, which in 2005 was sold to GalaxoSmithKline for over \$1.4 billion. He provided financing, investment bankers, substantial sponsorship and successfully advocated for the restructuring of management. Mr. Karkus has 25 years of experience in securities and capital markets including 2 years with Fahnstock & Co. Inc., a full-service brokerage firm, where he was Senior Vice President, Director of Institutional Equities, and 4 years at S.G. Warburg, an investment bank, where he was an institutional equity salesman and developed a large network of institutional investors. Mr. Karkus graduated with an MBA from Columbia University Graduate School of Business in 1984 where he received Beta Gamma Sigma honors. He graduated Magna Cum Laude from Tufts University in 1981.

Robert V. Cuddihy, Jr. will earn a salary of \$275,000 per year as Chief Operating Officer, an annual grant of \$50,000 in the Company’s common stock, and will receive regular benefits routinely provided to senior executives of the Company. There is no employment agreement memorializing the agreement between Mr. Cuddihy and the Company. Mr. Cuddihy acted as a financial consultant to the Company from June 19, 2009 through July 15, 2009. Mr. Cuddihy does not have a family relationship with any director or executive officer of the Company, nor is he a party to any “related person” transactions with the Company.

Mr. Cuddihy, age 49, has over 20 years of experience as the Chief Operating Officer and/or Chief Financial Officer of two public companies, iDNA Inc. which focused on corporate communications, and HMG Worldwide Corporation which focused on retail, planning and merchandising. He served as Chief Financial Officer and Treasurer of iDNA Inc. from September 2001 through February 2009 and Secretary from January 2003 through February 2009. From July 1987 to March 2001, Mr. Cuddihy was the Chief Financial Officer of HMG Worldwide Corporation, and also served as a director of such entity from February 1998 to May 2001. Most recently, Mr. Cuddihy served as the President of Shannon Hill Associates, providing due diligence, financial structuring, and transaction negotiation services for M&A, restructurings and divestitures.

---

**Item 8.01. Other Events.**

As previously reported, the Board of Directors of the Company approved on June 23, 2009 a compensation plan for non-employee directors in which directors would earn a monthly board fee of \$3,000, payable in both cash and restricted stock of the Company. The Company will continue to pay the board fees of directors in cash, and will not pay directors in the form of restricted stock, until such time that the shareholders of the Company have approved an equity compensation plan for the Company, consistent with NASDAQ rules.

A copy of a press release issued by the Company discussing the events described in this Form 8-K is filed as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<u>No.</u>	<u>Description</u>
99.1	Press Release of the Company, dated July 17, 2009

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**The Quigley Corporation**

By: \_\_\_\_\_  
Gerard M. Gleeson  
Vice President and Chief  
Financial Officer

Date: July 21, 2009

EXHIBIT INDEX

<u>No.</u>	<u>Description</u>
99.1	Press Release of the Company, dated July 17, 2009



**FOR IMMEDIATE RELEASE**

**CONTACT:**

Ted Karkus  
Chairman of the Board, CEO  
The Quigley Corporation  
(215) 345-0919

Media  
Karen Pineman  
G.S. Schwartz & Co.  
212.725.4500  
kpineman@schwartz.com

Investor Relations  
Carl Hymans  
G.S. Schwartz & Co.  
212.725.4500  
carlh@schwartz.com

**TED KARKUS NAMED CEO OF THE QUIGLEY CORPORATION**

**--Robert V. Cuddihy, Jr. Named Chief Operating Officer--**

DOYLESTOWN, Pa., July 17, 2009 -- **The Quigley Corporation**, (Nasdaq: QGLY), [www.quigleyco.com](http://www.quigleyco.com), today announced that Ted Karkus, Chairman of the Board of The Quigley Corporation, has been appointed Chief Executive Officer by the Board of Directors of the Company. The Company also announced today that Robert V. Cuddihy, Jr. has been appointed Chief Operating Officer.

Ted Karkus recently conducted a successful proxy contest which resulted in his slate of directors being elected to the Board of Directors of the Company. He had been serving as interim CEO since June 12, 2009. Mr. Karkus has 25 years of Wall Street experience and since 1996 has been providing management consulting services to emerging-growth companies. These services have included the structuring and raising of working capital as well as assisting management in developing operational, marketing and financial strategies. Mr. Karkus was instrumental in assisting the turnaround of ID Biomedical, an influenza vaccine manufacturer, which in 2005 was sold to GalaxoSmithKline for over \$1.4 billion. He assisted the Company in establishing relationships with investment bankers, personally provided financing as well as substantial sponsorship, and successfully advocated for the restructuring of management.

Robert V. Cuddihy, Jr. has over 20 years of experience as the Chief Operating Officer and/or Chief Financial Officer of two public companies, HMG Worldwide Corporation which focused on retail, planning and merchandising, and iDNA Inc. which focused on corporate communications. Most recently, Mr. Cuddihy served as the President of Shannon Hill Associates providing due diligence, financial structuring, and transaction negotiation services for M&A, restructurings and divestitures.

The Board of Directors offered, and Mr. Karkus accepted, the position of CEO at a salary of \$750,000 (plus customary employee benefits). The Board also offered, and Mr. Cuddihy accepted, the position of COO at a base salary of \$275,000 (plus customary employee benefits) as well as an annual grant of \$50,000 in the Company's common stock. Mr. Karkus was formerly the interim CEO and Mr. Cuddihy was formerly a financial consultant to the Company while the Board was reviewing the Company's operations.

The Company does not have a currently effective equity compensation plan. Accordingly, neither Mr. Karkus nor the current board members may receive stock options or stock grants unless and until such time as an equity incentive plan is adopted by shareholders.

---

Recent resignations of senior executives and further reductions of head count have reduced the Company's overall payroll expense by approximately \$1.75 million per year, compared to 2008 levels, even after the hiring of Mr. Karkus and Mr. Cuddihy.

The Compensation Committee of the Board of Directors was assisted by Buck Consultants in formulating the CEO compensation arrangement and has been engaged as the compensation consultant to the Compensation Committee.

Buck Consultants, a wholly owned subsidiary of ACS, began in 1916 and has grown into a diversified firm that provides consulting services to both public and private entities, large and small, covering the entire employee benefit, compensation and broader human resource management fields. Today, Buck is one of the leading benefit and compensation consulting and actuarial services firms in the world with more than 1,500 professionals worldwide.

#### **About The Quigley Corporation**

The Quigley Corporation (Nasdaq: QGLY, <http://www.Quigleyco.com>) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE® family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc. consists of an FDA approved facility to manufacture COLD-EEZE® lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (<http://www.QuigleyPharma.com>) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

#### **Forward-Looking Statements**

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.